JSON
Oksa L, Moisio S, Maqbool K, Kramer R, Nikkilä A, Jayasingha B, Mäkinen A, Foroughi-Asl H, Rounioja S, Suhonen J, Krali O, Voutilainen M, Lahnalampi M, Vepsäläinen K, Huang S, Duque-Afonso J, Hauer J, Nordlund J, Wirta V, Lohi O, Heinäniemi M
Leukemia 39 (9) 2125-2139 [2025-09-00; online 2025-07-09]
ETV6::RUNX1 leukemia is the second most common subtype of childhood B cell acute lymphoblastic leukemia (B-ALL). Although it generally has a low relapse risk, a significant proportion of B-ALL relapses occur within this subtype due to its relatively high incidence. Measurable residual disease at the end of induction therapy is a well-established biomarker predicting treatment outcomes, while no genomic biomarkers are routinely applied in clinics. In this study, we used multiomic data from ETV6::RUNX1 leukemias to identify genomic features predictive of therapy response at disease presentation. In the deeply characterized sub-cohort we discovered that fast-responding cases frequently exhibited the APOBEC mutational signature and the gene expression signature of high cell cycle activity. In contrast, rearrangements of IGK genes were more frequent in slow responders. Additionally, response-related mutations were identified in transcriptional regulators and tumor suppressor genes (INTS1, NF1, TP53). Copy number analysis revealed that fast responders harbored more frequent deletions of chr12 p-arm, leading to transcriptomic changes affecting genes associated with induction therapy response (KRAS, FKBP4), while a shorter gain in chr12 was more common in slow responders. The identified genetic and transcriptomic markers of treatment sensitivity pave the way for improved disease classification at presentation, potentially improving clinical outcomes.
NGI Uppsala (SNP&SEQ Technology Platform) [Service]
National Genomics Infrastructure [Service]
PubMed 40634509
DOI 10.1038/s41375-025-02683-7
Crossref 10.1038/s41375-025-02683-7
pmc: PMC12380598
pii: 10.1038/s41375-025-02683-7